Early warning indicators for HIV drug resistance in adults in South Africa at 2 pilot sites, 2008-2010

Clinical Infectious Diseases

Volumn 58, Issue 11, 2014, Pages 1607-1614

  Dube, Nomathemba M ^a,b,c   Tint, Khin S ^c   Summers, Robert S ^a  

^a UNIVERSITY OF LIMPOPO   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Antiretroviral medicines; Drug resistance; Early warning indicators; HIV; Pharmacovigilance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL INDICATOR; CONTROLLED STUDY; DRUG MONITORING; EARLY WARNING INDICATOR; EARLY WARNING INDICATORS SCORE; FEMALE; FOLLOW UP; GOVERNMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PILOT STUDY; PRIORITY JOURNAL; SCORING SYSTEM; SOUTH AFRICA; WORLD HEALTH ORGANIZATION; ADOLESCENT; COHORT ANALYSIS; DRUG EFFECTS; DRUG UTILIZATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG UTILIZATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SOUTH AFRICA; YOUNG ADULT;

EID: 84900415341     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu109     Document Type: Article

References (20)

1. Statistics South Africa. Mid-year population estimates 2010. Available at: http://www.statssa.gov.za/publications/P0302/P03022010.pdf. Accessed 12 April 2012.
2. United Nations Joint Programme on HIV/AIDS. AIDS at 30: nations at a crossroad. Available at: http://www.unaids.org/unaids-resources/aidsat30/aids- at-30.pdf. Accessed 17 May 2012.
3. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available at: http://www.who.int/hiv/pub/ arv/advice/en/. Accessed 18 May 2012.
4. National Strategic Plan in HIV, STIs and TB. Available at: http://www.doh.gov.za/docs/stratdocs/2012/NSPfull.pdf. Accessed 21 October 2013.
5. South African Department of Health. Operational plan for comprehensive HIV and AIDS care, management, and treatment for South Africa. 2003. Available at: http://www.gov.za/documents/download.php?f=164714. Accessed 21 October 2013.
6. South African National Antiretroviral Treatment Guidelines, 2010. Available at: http://www.uj.ac.za/EN/CorporateServices/ioha/Documentation/ Documents/ART%20Guideline.pdf. Accessed 9 May 2012.
7. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004; 170:229-38.
8. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician 2011; 83:1443-51.
9. Dahab M, Kielmann K, Charalambous S, et al. Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. AIDS Patient Care STDs 2011; 25:53-9.
10. World Health Organization. HIV drug resistance early warning indicators: World Health Organizations to monitor HIV drug resistance prevention at antiretroviral treatment sites. Available at: http://www.unaids.org.br/ biblioteca/links/OPAS-OPS/OPAS%2014.pdf. Accessed 25 July 2011.
11. Sigaloff KCE, Hamers RL, Menke J, et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African Countries. Clin Infect Dis 2012; 54(suppl 4):S294-99.
12. World Health Organization. Assessment of the World Health Organization HIV Drug resistance early warning indicators: report of the EarlyWarning Indicator Advisory Panel Meeting, Geneva, Switzerland, 2011. Available at: http://apps.who.int/iris/bitstream/10665/75186/1/9789241503945-eng.pdf. Accessed 17 September 2012.
13. Epi Info [computer program]. Version 3.5.1. Atlanta, GA: Centers for Disease Control and Prevention, 2008.
14. Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up-contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007; 97:5.
15. Wang B, Losina E, Stark R, et al. Loss to follow-up in a community clinic in South Africa-roles of gender, pregnancy and CD4 count. S Afr Med J 2011; 101:253-257.
16. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherance compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5:e109.
17. El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 2011; 6:e17518.
18. Bateman C. Drug stock-outs: inept supply-chain management and corruption. S Afr Med J 2013; 103:600-602.
19. Schouten EJ, Jahn A, Ben-Smith A, et al. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc 2011; 14(suppl 1):S4.
20. Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-47.